Cytokine responsiveness of CD8(+) T cells is a reproducible biomarker for the clinical efficacy of dendritic cell vaccination in glioblastoma patients
/in Dendritic Cells, Glioblastoma, International PublicationsCurrent vaccine trials in glioblastoma: a review
/in Dendritic Cells, Glioblastoma, International PublicationsNovel approaches and mechanisms of immunotherapy for glioblastoma
/in Dendritic Cells, Glioblastoma, International PublicationsVaccination with dendritic cells loaded with allogeneic brain tumor cells for recurrent malignant brain tumors induces a CD4(+)IL17(+) response
/in Dendritic Cells, Glioblastoma, International PublicationsFighting fire with fire: the revival of thermotherapy for gliomas
/in Glioblastoma, Hyperthermia, International PublicationsMyeloid-derived suppressor cells in glioma
/in Glioblastoma, International Publications, IOZK VeröffentlichungenDendritic cell vaccine for recurrent high-grade gliomas in pediatric and adult subjects: clinical trial protocol
/in Dendritic Cells, Glioblastoma, International PublicationsDendritic cell-based immunotherapy for glioma: multiple regimens and implications in clinical trials
/in Dendritic Cells, Glioblastoma, International Publications
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer